Agenda-setting intelligence, analysis and advice for the global fashion community.
NAPA, California — The Business of Beauty Global Forum 2026 — now in its fourth consecutive year — saw senior executives, entrepreneurs, creatives and investors gather at Napa Valley’s Stanly Ranch from June 24-26 for three days of discussion, exploring the beauty industry’s biggest opportunities and challenges.
Alongside the main-stage programming, guests participated in a series of intimate lunch conversations, designed to examine some of the industry’s more consequential shifts in greater depth.
One such discussion, entitled “The Future of Skin Health,” brought together Dr Philippe Wolgen, chief executive of biopharmaceutical company Clinuvel, and Alice Gividen, director of content strategy at The Business of Fashion.
As prestige beauty enters a new phase of maturity, there has been a shift in authority towards clinical expertise and measurable outcomes. Today, consumers are navigating a growing ecosystem of clinics, diagnostics, devices, longevity platforms and science-led brands, raising new questions about who they trust, where value is created and what the future of skin health looks like.
McKinsey & Co.’s Future of Wellness 2025 survey estimates the sector is now worth $2 trillion globally, with healthy ageing, beauty and in-person wellness services among its fastest-growing categories as consumers increasingly view health and appearance as interconnected.
Those shifts are also redefining the boundaries of the beauty industry. Skincare is no longer viewed solely as a product category, but increasingly as part of a broader health and wellness ecosystem, where prevention, personalisation and long-term outcomes are shaping consumer demand. The same McKinsey & Co. research reflects this evolution — around half of consumers in the UK and US cite clinical effectiveness as a top purchasing factor, compared with just 20 percent who prioritise ‘clean” ingredients.
Against this backdrop, Clinuvel offers a distinct perspective. Founded as a pharmaceutical biotechnology company, it has spent decades developing treatments for patients with rare skin disorders, conducting research into pigmentation science, photoprotection and preventative skin health long before many of these themes entered mainstream beauty conversations.
Now, Clinuvel is bringing its pharmaceutical expertise into skincare, applying its patented peptide technology to develop products designed to protect, repair and stimulate the skin’s natural tanning response.
During the discussion, Wolgen explored what the beauty industry can learn from medicine’s long-term approach to patient care, why consumers are increasingly seeking evidence-based solutions, and how longevity, biotechnology and preventive healthcare are reshaping expectations for skincare.
Now, BoF shares the key insights from the conversation.
Move Beyond Brand Claims to Clinical Proof
Throughout the discussion, Wolgen argued that beauty is entering an era where scientific evidence and measurable outcomes will increasingly define consumer trust. As luxury consumers become more discerning and demand greater value, brands will need to demonstrate efficacy rather than simply communicate it.
“For highly effective drugs, there is real demand beyond what insurance companies are willing to reimburse,” said Wolgen. “We’ve also seen a growing demand for effective cosmetics. But first, we need to redefine what ‘effective’ means. Effective is efficacy based on data.”
Clinuvel has spent more than two decades developing peptide technologies within pharmaceuticals, generating extensive clinical evidence around DNA repair and pigmentation. Wolgen believes those same scientific foundations can now be translated into consumer beauty.
“When efficacy is that visible, it isn’t far-fetched to think you can translate that kind of technology into cosmetics,” he said.
Unlike traditional beauty claims, he argued, the next generation of products will increasingly be differentiated by long-term clinical validation and measurable biological outcomes. “Once you’ve built decades of clinical data, secured regulatory approval and built a pharmaceutical business around it, translating that science to consumers becomes the natural next step.”
Build Beauty Like a Healthcare Business
Perhaps Wolgen’s most distinctive insight was that beauty has as much to learn from healthcare’s business model as its science. Rather than optimising for transactions, pharmaceutical companies create value by supporting patients over many years — even decades — building trust through continuous care and measurable outcomes.
“What we’ve learned in pharmaceuticals is that if you care about each individual over a long period of time, the retention rate is astounding,” he said.
He contrasted that approach with businesses that simply provide a product before moving on. Clinuvel’s treatments can cost more than $50,000, yet the company continues to support patients over decades.
“The lifetime value becomes an order of magnitude higher if you care for people over ten or twenty years.”
For beauty brands, Wolgen argued, customer lifetime value should be understood less as repeat purchasing and more as an ongoing relationship grounded in trust. “The dialogue over decades is what we want to translate to consumers,” he shared.
He also reflected that the same philosophy has shaped Clinuvel itself. “Innovation takes a long time,” he said. “That’s the paradox of innovation.”
Position Skin Health Within the Longevity Economy
When BoF’s Gividen reflected on beauty’s role within the broader health and longevity ecosystem, Wolgen suggested that the highest-spending luxury consumers are increasingly directing discretionary spending towards preserving health rather than simply acquiring more products.
“When you already have everything, there is a diminishing marginal utility in buying the next luxury good,” he said. “The next thing we become concerned about is longevity.”
Rather than promising rejuvenation, he believes the opportunity lies in slowing the ageing process. “We can’t rejuvenate, but we can decelerate ageing.”
That broader shift is one reason Clinuvel is pursuing a hybrid model spanning pharmaceuticals and cosmetics. The company believes decades of medical research can create entirely new opportunities within beauty, particularly as consumers increasingly seek clinically backed approaches to skin health.
“We are truly a black swan,” said Wolgen. “We’re a pharmaceutical company with one arm in prescription medicine and one arm in cosmetics. There are not many companies in the world doing that.”
Reflecting on Clinuvel’s history, he added that some of the company’s biggest breakthroughs have come from looking beyond its own category. “Sometimes you need to do things very differently,” he said. “You need a different perspective.”
This is a sponsored feature paid for by Clinuvel as part of a BoF partnership.
